The promise of biomarkers in Psoriatic Arthritis: Moving towards precision medicine - PubMed

6 hours ago

Psoriatic arthritis (PsA) is a heterogeneous disease with challenges in diagnosis and treatment response variability.
Biomarkers from metabolic, immunological, and genetic pathways offer potential for precision medicine in PsA.
A distinct metabolic endotype involves altered apolipoproteins and gut metabolites.
Immunological signatures include pathogenic tissue-resident memory T cells.
Genetic and multi-omic analyses, aided by machine learning, identify susceptibility loci and signaling pathways.
Cytokine profiles and extracellular matrix markers show promise for treatment stratification and monitoring.
Specific chemokines and inflammatory indices predict the transition from psoriasis to PsA, enabling early intervention.
Integration of diverse biomarker domains through machine learning may improve diagnosis and personalized therapy.
The review outlines a path toward better long-term outcomes for PsA patients.

Hasty Briefsbeta